Merck feels pain of Schering ops integration

Difficulties integrating the manufacturing and supply chain operations of two big pharma companies is crimping the supply of women's health products. As Merck continues to swallow Schering-Plough following the late 2009 acquisition, legacy systems and processes are proving a hindrance to efforts aimed at operations consistency.

The drugmaker says it's been managing through temporary supply shortages of some women's health products since the end of last year, Dow Jones reports. It's "working to resolve these issues."

Plans announced last year included the closing of eight manufacturing plants as well as R&D sites for cost savings. The news outlet reports Merck has also faced manufacturing and supply problems in its vaccine operations.

- here's the story

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.